Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial

CONCLUSIONS: Patients free from events at the end of the first year post-PCI and who adhered to their prescribed regimen had a reduced risk of ischaemic events compared to aspirin monotherapy in the second year post-PCI.CLINICALTRIALS: gov: NCT01813435.PMID:35260381 | DOI:10.4244/EIJ-D-21-00870

Source: EuroIntervention - March 9, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Masafumi Ono Hironori Hara Hideyuki Kawashima Chao Gao Rutao Wang Joanna J Wykrzykowska Jan J Piek Scot Garg Christian Hamm Philippe Gabriel Steg Marco Valgimigli Stephan Windecker Pascal Vranckx Yoshinobu Onuma Patrick W Serruys Source Type: research